- Trial phase
- Approved
- Time to market
- Lifyorli is already approved and commercially available in the U.S. for platinum-resistant ovarian cancer (approved March 25, 2026). A decision on the Cushing's syndrome indication is expected by December 17, 2026. A Marketing Authorization Application (MAA) is also under review by the European Medicines Agency.
- Why 7/10
- The next hard, dated catalyst is the FDA PDUFA target action date of December 17, 2026 for relacorilant's NDA resubmission in Cushing's syndrome, approximately 6 weeks away. This is a major label-expansion binary for a drug that is already approved and generating revenue, at a company with other commercial products (Korlym) and pipeline programs, so it scores a 7 rather than higher.
The next major catalyst is the December 17, 2026 PDUFA decision on relacorilant's NDA resubmission for Cushing's syndrome. An approval would open a large endocrinology market (currently served by Korlym, which generated ~$498M in the first nine months of 2026) and could significantly expand the drug's total addressable market beyond the already-approved ovarian cancer indication. A second CRL would be a major setback for the Cushing's franchise.
Price Chart
Executive Summary
Lifyorli (relacorilant) is Corcept Therapeutics' second commercial drug and the first FDA-approved selective glucocorticoid receptor antagonist (SGRA). It was approved on March 25, 2026 in combination with nab-paclitaxel for platinum-resistant ovarian cancer, based on the Phase 3 ROSELLA trial showing a 35% reduction in risk of death. The launch is accelerating rapidly, with Q3 2026 revenue of $91.4 million (up 92% quarter-over-quarter). The next major catalyst is the December 17, 2026 PDUFA date for relacorilant's NDA resubmission in Cushing's syndrome, a large endocrinology market where Corcept already sells Korlym (mifepristone). The stock has pulled back sharply from its 52-week high amid a broader market selloff, but analyst consensus remains strongly bullish with a mean price target of $141.
How It Works
Lifyorli (relacorilant) is a selective glucocorticoid receptor antagonist (SGRA). It blocks the activity of the hormone cortisol by competing for binding at the glucocorticoid receptor. In cancer, cortisol signaling can help tumors resist chemotherapy, so blocking it makes cancer cells more sensitive to treatment. In Cushing's syndrome, the drug reduces the harmful effects of excess cortisol in the body.
Trial Status
Lifyorli was approved by the FDA on March 25, 2026 based on the Phase 3 ROSELLA trial (N=381) in platinum-resistant ovarian cancer, which met its primary endpoint of overall survival. The drug was added to NCCN Guidelines as a preferred regimen. A separate Phase 3 GRACE trial in Cushing's syndrome supported an NDA resubmission now under FDA review with a PDUFA date of December 17, 2026. The company is also exploring relacorilant in other solid tumors and metabolic indications.
The Two-Sided Case
Upcoming Catalysts
- December 17, 2026: FDA PDUFA target action date for relacorilant NDA resubmission in Cushing's syndrome (hypercortisolism)
- EMA decision on Marketing Authorization Application (MAA) for relacorilant in platinum-resistant ovarian cancer
- Potential label expansion data from ongoing trials in other solid tumors and metabolic indications
Source Filing
The SecBot filing or press-release report that triggered this drug report:
CORCEPT THERAPEUTICS INC 8-K CORT ·Originating report